Premature Aging of Cardiovascular/Platelet Function in Polycystic Ovarian Syndrome - 19/06/13

Abstract |
Objective |
The objective of this study was to compare the impact of aging on nitric oxide (NO) modulation of platelet and vascular function in healthy women and women with polycystic ovary syndrome.
Methods and Results |
A case-control study of women ages 18 to 60 years, comparing women with polycystic ovarian syndrome against age-matched healthy controls, was performed. A total of 242 women, of whom 109 had polycystic ovarian syndrome (based on Rotterdam criteria), participated in the study. Women who were pregnant or on clopidogrel were excluded from the study. Inhibition of platelet aggregation by nitric oxide (primary outcome measure), vascular endothelial function, plasma concentrations of NG, NG-dimethyl-L-arginine (ADMA), endothelial progenitor cell count, and high-sensitivity C-reactive protein (markers of endothelial dysfunction and inflammation) were assessed. With increasing age in control women, there was progressive attenuation of platelet responses to NO, impairment of endothelial function, and elevation of ADMA levels (P ≤.001). Irrespective of age, women with polycystic ovarian syndrome exhibited greater impairment of all these parameters (all P <.05, 2-way analysis of variance) and demonstrated these anomalies earlier in life.
Conclusions |
Normal aging in women is associated with attenuation of NO-based signaling in platelets and blood vessels. In women with polycystic ovarian syndrome, these changes are present from early adult life and may contribute to premature atherogenesis.
El texto completo de este artículo está disponible en PDF.Keywords : Aging, Nitric oxide, Polycystic ovary syndrome, Women
Esquema
| Funding: This study was funded in part by the Cardiovascular Lipid Disorders research grant (Pfizer, Australia), and departmental funding. WC and AS were recipients of postgraduate research scholarships from the University of Adelaide and Cardiovascular Lipid Disorders research grants (Pfizer, West Ryde, NSW, Australia). |
|
| Conflict of Interest: None. |
|
| Authorship: All authors had access to the data and a role in preparation of the manuscript. |
Vol 126 - N° 7
P. 640.e1-640.e7 - juillet 2013 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?
